Financial Performance - Operating revenue for the first quarter reached CNY 516,817,163.09, representing an 83.61% year-on-year increase [5]. - Net profit attributable to shareholders was CNY 5,141,403.06, a turnaround from a loss of CNY 25,032,741.60 in the same period last year [5]. - The SPD business achieved a remarkable revenue growth of 189.25% year-on-year [10]. - The company's operating revenue for Q1 2021 was RMB 516,817,163.09, representing an increase of 83.61% compared to RMB 281,472,317.63 in Q1 2020, primarily due to the impact of the pandemic in the previous year [14]. - Operating profit for Q1 2021 was RMB 16.73 million, recovering from an operating loss of RMB 23.54 million in Q1 2020 [24]. - Net profit for Q1 2021 was RMB 13.93 million, compared to a net loss of RMB 27.14 million in Q1 2020, marking a turnaround [26]. - The company’s total comprehensive income for Q1 2021 was RMB 13.20 million, a recovery from a loss of RMB 27.14 million in Q1 2020 [26]. Cash Flow and Investments - The net cash flow from operating activities improved significantly, with a reduction in losses to CNY -11,996,421.08 from CNY -79,571,848.31, marking an 84.92% improvement [5]. - The company's cash flow from operating activities showed a net outflow of RMB 11,996,421.08, an improvement of 84.92% compared to a net outflow of RMB 79,571,848.31 in Q1 2020, indicating better collection of receivables [15]. - The company reported a net cash outflow from investing activities of RMB 40,285,175.42, which is not comparable to the previous year's outflow of RMB 22,146,134.83 due to increased investments [15]. - The company reported a total cash outflow from investing activities of CNY 40,345,175.42 in Q1 2021, compared to CNY 24,146,134.83 in Q1 2020, indicating an increase of approximately 67.3% [31]. Assets and Liabilities - Total assets increased by 3.12% to CNY 4,028,170,359.41 compared to the end of the previous year [5]. - Total assets as of March 31, 2021, amounted to RMB 3,059,415,660.72, up from RMB 2,928,180,427.26 at the end of 2020, reflecting growth in current assets [16]. - Total liabilities increased to CNY 2,207,828,298.64 from CNY 2,103,795,321.52, reflecting a growth of about 4.9% [18]. - Current liabilities decreased slightly to CNY 1,385,644,290.31 from CNY 1,388,178,679.65, a reduction of about 0.2% [17]. - Non-current liabilities rose to CNY 822,184,008.33, compared to CNY 715,616,641.87, indicating an increase of approximately 14.9% [18]. - Owner's equity totaled CNY 1,820,342,060.77, up from CNY 1,802,544,801.83, marking an increase of approximately 1.0% [18]. Shareholder Information - The total number of shareholders reached 10,976, with the top ten shareholders holding a combined 61.78% of shares [12]. - The company reported RMB 5,099,229.86 in deferred income tax liabilities, indicating future tax obligations [37]. Research and Development - Research and development expenses surged to RMB 9,603,868.15, a significant increase of 930.75% from RMB 931,740.33, driven by ongoing investments in information technology and product development [14]. - Research and development expenses increased to RMB 9.60 million in Q1 2021, up from RMB 0.93 million in Q1 2020, reflecting a focus on innovation [24]. Market and Future Outlook - The company aims to continue expanding its market presence and investing in new technologies to drive future growth [24]. - Future outlook and performance guidance were not provided in the report [41]. - There were no mentions of market expansion or acquisitions in the earnings call [41].
塞力医疗(603716) - 2021 Q1 - 季度财报